Alzamend Neuro Inc (ALZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
| 04-2022 | 01-2022 | 10-2021 | 07-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,362 | -8,493 | -5,920 | -2,320 | N/A |
| Depreciation Amortization | 4 | N/A | N/A | N/A | 0 |
| Other Working Capital | 1,327 | 278 | 601 | 353 | -153 |
| Other Operating Activity | 4,417 | 3,164 | 2,050 | 744 | 2,487 |
| Operating Cash Flow | $-6,614 | $-5,052 | $-3,269 | $-1,223 | $2,335 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -107 | N/A | N/A | N/A | 0 |
| Other Investing Activity | 0 | 0 | 0 | 0 | 101 |
| Investing Cash Flow | $-107 | $N/A | $N/A | $N/A | $101 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -59 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 6,000 | 2,000 | 2,000 | 2,000 | N/A |
| Other Financing Activity | 12,914 | 12,913 | 12,912 | 12,912 | 2,600 |
| Financing Cash Flow | $18,855 | $14,913 | $14,912 | $14,912 | $2,600 |
| Beginning Cash Position | 1,929 | 1,929 | 1,929 | 1,929 | N/A |
| End Cash Position | 14,064 | 11,790 | 13,573 | 15,618 | N/A |
| Net Cash Flow | $12,135 | $9,861 | $11,643 | $13,689 | $5,035 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,614 | -5,052 | -3,269 | -1,223 | 2,335 |
| Capital Expenditure | -107 | N/A | N/A | N/A | N/A |
| Free Cash Flow | -6,721 | -5,052 | -3,269 | -1,223 | 2,335 |